
Contributions
Abstract: EP1790
Type: ePoster
Abstract Category: Therapy - disease modifying - 32 Others
Background and goals: Around 100,000 people are currently diagnosed with Multiple Sclerosis (MS) in France. To date, available therapies for the disease do not cure MS and only prevent flares in the relapsing-remitting forms. The objective of the analysis was to describe the therapeutic management of patients with MS.
Method: The main French National Health Insurance database cover about 90% of the French population. Data from a random sample of ≈ 600,000 patients (1/97th) registered in this claim database were used to identify adults MS patients through their Long standing condition status (ICD-10 code: G35)/ hospital stays during the study period referencing MS as main diagnosis or related/ at least one reimbursement of an MS-specific drug over the 2007-2014 period. Treatment sequences were identified considering date of delivery of MS therapies in the database.
Results: A total of 940 patients were included in the prevalent MS population on January 1st, 2014. On average they were 50.9 (± 13.7) years old. 71.4% of patients were female. Nearly all patients (91.7%) were visited at least once during the year by a GP and 38.9% a neurologist. Overall, 44.3% of patients have received at least one delivery of a primary therapy for MS in 2014 mostly beta-interferons and assimilated (28.8%), selective oral immunosuppressant (6.1%) non-selective oral immunosuppressant (5.7%), humanized monoclonal antibody anti-alpha-4 integrin (5.0%), oral Nrf2 pathway activator (3.1%), oral selective immunomodulatory (2.0%), chimeric anti-CD20 antibody (0.3%). 24.4% of patients had a symptomatic treatment at least once during the year (baclofen 17.7%) and 9.3% at least one delivery of injectable corticosteroids. A longitudinal analysis over 2007-2014 show most patients were treated discontinuously with rather long period of time without primary therapies for MS. In 2014, 22.1% of patients beneficiated of technical aids for their disabilities and 46.9% of patients had at least one physiotherapy session during the year. Finally, 6.2% of patients were hospitalized for MS for an average duration of 3.6 days.
Conclusions: Management strategies in MS were modified in the last decade with the marketing of disease-modifying treatments. However, in our sample, slightly more than half patients did not receive any primary therapies for MS while a significant part of patients continue to experience symptoms and disabilities associated with MS.
Disclosure:
Authors Bruno Detournay and Mathias Cousin are employees of Cemka-Eval a consultancy firm which was contracted by Roche France for this study; Bruno Detournay also received honoraria for consultancy from Merck Sharp and Dohme, Novo-Nordisk, Sanofi, Boehringer-Ingelheim, Pfizer.
Valérie Machuron, Paul-Henri Depoortere, David Pau are employed by Roche France. Julie Gourmelen has no conflict of interest
This study was funded by Roche France.
Abstract: EP1790
Type: ePoster
Abstract Category: Therapy - disease modifying - 32 Others
Background and goals: Around 100,000 people are currently diagnosed with Multiple Sclerosis (MS) in France. To date, available therapies for the disease do not cure MS and only prevent flares in the relapsing-remitting forms. The objective of the analysis was to describe the therapeutic management of patients with MS.
Method: The main French National Health Insurance database cover about 90% of the French population. Data from a random sample of ≈ 600,000 patients (1/97th) registered in this claim database were used to identify adults MS patients through their Long standing condition status (ICD-10 code: G35)/ hospital stays during the study period referencing MS as main diagnosis or related/ at least one reimbursement of an MS-specific drug over the 2007-2014 period. Treatment sequences were identified considering date of delivery of MS therapies in the database.
Results: A total of 940 patients were included in the prevalent MS population on January 1st, 2014. On average they were 50.9 (± 13.7) years old. 71.4% of patients were female. Nearly all patients (91.7%) were visited at least once during the year by a GP and 38.9% a neurologist. Overall, 44.3% of patients have received at least one delivery of a primary therapy for MS in 2014 mostly beta-interferons and assimilated (28.8%), selective oral immunosuppressant (6.1%) non-selective oral immunosuppressant (5.7%), humanized monoclonal antibody anti-alpha-4 integrin (5.0%), oral Nrf2 pathway activator (3.1%), oral selective immunomodulatory (2.0%), chimeric anti-CD20 antibody (0.3%). 24.4% of patients had a symptomatic treatment at least once during the year (baclofen 17.7%) and 9.3% at least one delivery of injectable corticosteroids. A longitudinal analysis over 2007-2014 show most patients were treated discontinuously with rather long period of time without primary therapies for MS. In 2014, 22.1% of patients beneficiated of technical aids for their disabilities and 46.9% of patients had at least one physiotherapy session during the year. Finally, 6.2% of patients were hospitalized for MS for an average duration of 3.6 days.
Conclusions: Management strategies in MS were modified in the last decade with the marketing of disease-modifying treatments. However, in our sample, slightly more than half patients did not receive any primary therapies for MS while a significant part of patients continue to experience symptoms and disabilities associated with MS.
Disclosure:
Authors Bruno Detournay and Mathias Cousin are employees of Cemka-Eval a consultancy firm which was contracted by Roche France for this study; Bruno Detournay also received honoraria for consultancy from Merck Sharp and Dohme, Novo-Nordisk, Sanofi, Boehringer-Ingelheim, Pfizer.
Valérie Machuron, Paul-Henri Depoortere, David Pau are employed by Roche France. Julie Gourmelen has no conflict of interest
This study was funded by Roche France.